Related Experiment Video
Updated: Apr 19, 2026

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments
Published on: October 25, 2024
Non-transpeptidase binding arylthioether β-lactams active against Mycobacterium tuberculosis and Moraxella
Tim N Beck1, Dina Lloyd1, Rostislav Kuskovsky1
1Department of Chemistry, American University, Washington, DC 20016, USA.
Abstract:
The prevalence of drug resistance in both clinical and community settings as a consequence of alterations of biosynthetic pathways, enzymes or cell wall architecture is a persistent threat to human health. We have designed, synthesized, and tested a novel class of non-transpeptidase, β-lactamase resistant monocyclic β-lactams that carry an arylthio group at C4. These thioethers exhibit inhibitory and cidal activity against serine β-lactamase producing Mycobacterium tuberculosis wild type strain (Mtb) and multiple (n=8) β-lactamase producing Moraxella catarrhalis clinical isolates.
Related Concept Videos
Inhibitors of Gram-positive Cell Wall Synthesis
Clinical Significance of Antibiotic Resistance
Mechanism of Antibiotic Resistance in MRSA
Inhibitors of Bacterial Protein Synthesis
Bacterial Phylum Actinobacteria
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...

